Browsing by Autor "Sergio Rojas"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item type: Item ,
    Early Latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American collaborative retina study (PACORES) group
    (BioMed Central, 2026) Lihteh Wu; Sergio Rojas; Xi Rao; Michael Politis; José Antonio Roca; Márcio Bittar Nehemy; Berrocal Mh; Jans Fromow-Guerra; Karen Barraza-Lino; Carlos Lopez
    To report the early visual outcomes of eyes with a variety of retinal conditions that were treated with intravitreal faricimab during routine clinical practice in Latin America. Retrospective multicenter case series of 757 eyes of 732 patients who underwent at least one intravitreal injection of faricimab and had a least 4 weeks of follow-up. Our cohort consisted of 392 eyes with neovascular age-related macular degeneration (NV-AMD) (naive = 105; prior tx = 287); 225 with DME (naive = 74; prior tx = 151); 50 with central retinal vein occlusion (CRVO) (naive = 29; prior tx = 21); 20 with previously treated branch retinal vein occlusion (BRVO) and 69 (naive = 25; prior tx = 44) with other conditions. After a mean follow-up of 26.6 weeks and 4 injections, eyes with treatment naive NV-AMD eyes gained 9.1 letters (p < 0.0001) with a last mean treatment interval of 9.5 weeks. Previously-treated NV-AMD eyes gained 6.6 to 9.5 letters (p = 0.00146 and p < 0.0001) after a mean follow-up of 29 to 42 weeks and 3.8 to 4.3 injections with a last mean treatment interval of 9.2 to 12.1 weeks. In treatment naive diabetic macular edema (DME) eyes, after a mean follow-up of 24.8 weeks and 4.2 injections, there was a gain of 12 letters (p < 0.0001) with a last mean treatment interval of 9.2 weeks. In previously-treated DME eyes after a mean follow-up of 27.2 to 44.2 weeks and 3.8 to 3.9 to injections, there was a gain of 6.1 to 11.7 letters (p < 0.0001) with a last mean treatment interval of 9.6 to 15.2 weeks. Treatment-naive CRVO eyes gained 22.6 letters (p = 0.00369) after a mean follow-up of 26.2 weeks and 3.7 injections. Previously treated CRVO eyes gained 9.8 letters (0.5233) after a mean follow-up of 21.8 weeks and 3.4 injections. Previously-treated BRVO eyes gained 5.4 letters (p = 0.00862) after a mean follow-up of 28.1 weeks and 3.5 injections and a last treatment interval of 11.1 weeks. A total of 38 eyes discontinued treatment with faricimab and switched back to aflibercept. There were 3 cases of anterior uveitis that were treated with topical steroids. None of the eyes developed infectious endophthalmitis or occlusive retinal vasculitis. The early Latin American experience with faricimab is promising. On average treated eyes had functional and anatomic gains from baseline.
  • Thumbnail Image
    Item type: Item ,
    Lyophilized amniotic membrane patches are a safe and effective treatment for rhegmatogenous lesions in combined tractional and rhegmatogenous retinal detachment: A prospective interventional study
    (2024) Ángel García-Vásquez; Sergio Rojas; Geovanni Ríos-Nequis; Abel Ramírez-Estudillo
    <title>Abstract</title> <bold>Objetives</bold>: This study was performed to evaluate the safety and effectiveness of a lyophilized amniotic membrane (LAM) as a patch for the treatment of retinal breaks and to describe the structural changes at the implantation site. <bold>Design</bold>: prospective, interventional study. <bold>Subjects</bold>: Patients with diabetic retinopathy and combined tractional and rhegmatogenous retinal detachment. <bold>Methods</bold>: Patients were organized into 3 groups according to the number of rhegmatogenous lesions: those in group A had a single break, those in group B had two breaks, and those in group C had three or more breaks. The location of the break was also evaluated as either superior or inferior. <bold>Main outcomes:</bold> Safety was evaluated and defined as a lack of adverse events or the absence of damage to the retinal tissue and intraocular structures. Efficacy was determined by evaluating SD-OCT images to assess whether complete coverage of the retinal break favouring the proximity of the edges and closure of the retinal break was achieved. <bold>Results</bold>: Of a total of 23 eyes of 23 patients, 22 (95.6%) achieved retinal repair without associated complications. Patients with 2 or fewer rhegmatogenous lesions located inthe superior sector had a better anatomical result as they achieved 100% surgical success. The structural changes observed by SD-OCT showed adequate adaptation of the lyophilized patch and complete closure of the rhegmatogenous lesion with no alterations in the adjacent tissue. <bold>Conclusions</bold>: The LAM patch seems to be safe and effective, as it promotes therapeutic closure of rhegmatogenous lesions without damaging the retinal architecture adjacent to the implantation site.